Paseman & Associates

Paseman & Associates functions as William Paseman's strategic vehicle, investing primarily in early-stage technology companies. It provides capital and operational expertise for growth acceleration. The firm also develops quantitative finance models for investment optimization and supports research in non-invasive medical diagnostics, blending financial insight with technical innovation. This integrated approach applies seasoned experience across various high-impact sectors.

William Paseman established Paseman & Associates as a consulting firm in the early 1990s, leveraging his Silicon Valley background, including co-founding Calico Commerce. By 2000, it became his dedicated platform for angel investing, driven by the belief that experienced guidance and seed capital accelerate technological ventures. This evolution reflects his transition from a successful founder to a strategic enabler of new enterprises.

The firm supports innovative startups with strategic investments and expert guidance. Its quantitative analyses and medical research also aid collaborative partners. Paseman & Associates aims to foster disruptive technologies where data-driven solutions and novel medical applications create significant value, shaping future industries. This forward-looking vision positions the firm at the intersection of capital, innovation, and societal advancement.

High-Level Overview

Paseman & Associates is an angel investment firm led by Bill Paseman, focusing on early-stage investments in startups, particularly in Silicon Valley.[4][5] The firm emphasizes supporting high-potential teams by leveraging Paseman's extensive experience since 1980, with an investment philosophy centered on minimizing risk through strong business plans and quantitative finance insights, such as extensions to Modern Portfolio Theory.[5][8] Key sectors include healthcare and biotech, as evidenced by recent investments like $41.9 million in Cresilon's Series A for hemostatic products in wound healing.[2] It plays a niche role in the startup ecosystem by providing angel capital to innovative biomedical and tech ventures, contributing to early traction for companies addressing unmet medical needs.[1][2]

Origin Story

Bill Paseman founded Paseman & Associates as a personal angel investment vehicle after arriving in Silicon Valley in 1980.[4][5] With a background in quantitative finance—dating back to 1978 correspondence on topics like Ed Thorpe's theories and portfolio models—Paseman transitioned into angel investing, sharing resources on his site for corporate goals, team expectations, and risk reduction in startups.[5][8] The firm's evolution reflects Paseman's long-term Silicon Valley presence, shifting from personal finance explorations to active early-stage investments, including high-profile healthcare deals like Cresilon in 2025.[2][4]

Core Differentiators

• Personalized Angel Model: Operates as a solo-led firm by Bill Paseman, offering hands-on guidance drawn from decades in Silicon Valley, emphasizing risk retirement via robust business plans.[4][5][8]
• Quantitative Edge: Integrates advanced finance tools, such as software models extending the Single-index Asset Pricing Model (\(R_i = \alpha_i + \beta_i R_m + \epsilon_i\)) for better portfolio performance.[5]
• Targeted Track Record: Proven in biotech, e.g., investing in Cresilon's $41.9M Series A alongside Catalio Capital for energy-based medical devices.[1][2]
• Network and Resources: Provides curated lists of angel investing tools and expectations for investee teams, fostering disciplined growth.[5][8]

Role in the Broader Tech Landscape

Paseman & Associates rides the wave of biotech innovation, particularly in underserved areas like wound healing and oncology, amid surging demand for advanced medical devices post-2020s health crises.[2] Timing aligns with 2025's venture boom in healthcare tech, where firms like Cresilon benefit from market forces such as aging populations and minimally invasive procedure trends.[2] By funding pivotal Series A rounds, it influences the ecosystem through de-risking startups, enabling follow-on investments from larger VCs and accelerating tech transfer from labs to clinics.[1][2][8]

Quick Take & Future Outlook

Paseman & Associates is poised to deepen its healthcare portfolio amid AI-driven drug discovery and precision medicine trends, potentially expanding into adjacent tech like imaging (e.g., Leadoptik analogs).[2][5] Rising interest in quantitative tools for volatile markets could amplify its influence, with Paseman's models aiding resilient startup funding. As angel capital bridges seed-to-growth gaps, expect evolved impact through co-investments, sustaining its niche in Silicon Valley's enduring startup engine—echoing its risk-focused roots for enduring returns.[5][8]